ConductScience.org, home

Comparison · NCT02686138-3df9fb82

50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks. Trial comparisons, record NCT02686138-3df9fb82. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02686138-3df9fb82

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4130.3580.47wilson
Risk in group 20.310.260.364wilson
Risk difference, group 1 minus group 20.1030.02560.179newcombe hybrid score
Risk ratio, group 1 over group 21.331.071.66log
Odds ratio, group 1 over group 21.571.122.19log
Number needed to treat, for one more participant with the outcome on 50mg BID than on Placebo9.715.639from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 150mg BIDTenapanor, 50mg BID (100mg total)~Tenapanor121293OG000
Group 2PlaceboPlacebo~Placebo93300OG001

Outcome

Type
SECONDARY
Title
Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks
Description
An overall CSBM responder is defined as a weekly responder for the first 13/26 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds yes to the following question; Did you feel like you completely emptied your bowels?
Time frame
26 weeks
Population

Source ClinicalTrials.gov

Trial

Title
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
NCT number
NCT02686138
Phases
PHASE3
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Lead sponsor
Ardelyx
Results first posted
2020-04-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02686138-3df9fb82